Clinical Trials Sponsored by Sentien Biotechnologies, Inc.

Total 97 results

Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

COVID-19 | Sepsis | Acute Kidney Injury

United States
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Stage IV Melanoma | Stage III Melanoma

United States
Adverum Biotechnologies, Inc.

Completed

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (ADVANCE)

Alpha 1-Antitrypsin Deficiency

United States
Adverum Biotechnologies, Inc.

Completed

ADVM-022 Intravitreal Gene Therapy for Wet AMD (OPTIC)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Adverum Biotechnologies, Inc.

Active, not recruiting

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Frontier Biotechnologies Inc.

Completed

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Covid19

United States
Adverum Biotechnologies, Inc.

Enrolling by invitation

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Frontier Biotechnologies Inc.

Completed

A Bridging Study of FB2001 in Healthy Subjects

COVID-19

China
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Mild to Moderate COVID-19

China
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Cancer | Refractory Cancer | Tumor, Solid

Israel, United States
Throne Biotechnologies Inc.

Not yet recruiting

Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19

Severe Acute Respiratory Syndrome (SARS) Pneumonia
Throne Biotechnologies Inc.

Recruiting

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Novome Biotechnologies Inc

Terminated

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Healthy Volunteers | Enteric Hyperoxaluria

United States, Canada
Adverum Biotechnologies, Inc.

Completed

Long-Term Follow-up Study of ADVM-043

Alpha-1 Antitrypsin Deficiency

United States
Frontier Biotechnologies Inc.

Unknown

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

HIV/AIDS

United States
Frontier Biotechnologies Inc.

Unknown

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

HIV/AIDS

China
Frontier Biotechnologies Inc.

Completed

Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

Chronic Low Back Pain

China
Vivos BioTechnologies, Inc.

Recruiting

Dental Appliance to Treat SDB in Children

Snoring | Sleep-Disordered Breathing | Apnea, Obstructive | Upper Airway Resistance Syndrome

United States
Frontier Biotechnologies Inc.

Recruiting

Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

COVID-19

China
Taiga Biotechnologies, Inc.

Not yet recruiting

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Myelofibrosis | Acute Myelogenous Leukemia

Italy, Croatia
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
Taiga Biotechnologies, Inc.

Not yet recruiting

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Severe Combined Immunodeficiency

Israel
Adverum Biotechnologies, Inc.

Completed

ADVM-022 Intravitreal Gene Therapy for DME (INFINITY)

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Frontier Biotechnologies Inc.

Completed

A Study of FB2001 for Inhalation in Healthy Chinese Adults

COVID-19 Pandemic

China
Frontier Biotechnologies Inc.

Completed

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

HIV/AIDS

China
Frontier Biotechnologies Inc.

Completed

Test Albuvirtide in Experienced Patients (TALENT)

HIV Infections | AIDS

China
Adverum Biotechnologies, Inc.
Parexel

Active, not recruiting

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Neovascular Age-related Macular Degeneration

United States, France, United Kingdom
Adverum Biotechnologies, Inc.
Adverum Biotechnologies SAS, a wholly owned subsidiary of Adverum Biotechnologies...

Completed

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Friedreich's Ataxia

France
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Healthy

United States
Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States

3

Subscribe